['acromegaly', 'neuroendocrine tumors']
['octreotide fluidcrystal® injection depot']

        Inclusion Criteria:

        Acromegaly:

          -  Male or female patients ≥18 years of age

          -  Acromegaly currently treated with Sandostatin LAR

        NET:

          -  Male or female patients ≥18 years of age

          -  Functional, well-differentiated (Grade 1 or Grade 2) NET with symptoms of carcinoid
             syndrome (number of bowel movements and/or flushing)

          -  Currently treated with Sandostatin LAR for symptom control

        Exclusion Criteria:

        Acromegaly:

          -  Inadequate bone marrow function

          -  Abnormal coagulation or chronic treatment with warfarin or coumarin derivates

          -  Impaired liver, cardiac and/or renal function

          -  Known gallbladder, bile duct disease or pancreatitis

          -  Diabetes with poorly controlled blood glucose levels despite adequate therapy

          -  Hypothyroidisms not adequately treated

        NET:

          -  Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma,
             adenocarcinoid, pancreatic islet cell carcinoma, insulinoma, glucagonoma, gastrinoma,
             goblet cell carcinoid, typical and atypical lung carcinoids, large cell neuroendocrine
             carcinoma and small cell carcinoma

          -  Carcinoid syndrome refractory to treatment with conventional doses of somatostatin
             analogues (SSAs)

          -  Inadequate bone marrow function

          -  Abnormal coagulation or chronic treatment with warfarin or coumarin derivates

          -  Impaired liver, cardiac and/or renal function

          -  Known gallbladder, bile duct disease or pancreatitis

          -  Short-bowel syndrome

          -  Diabetics with poorly controlled blood glucose levels despite adequate therapy

          -  Hypothyroidism, not adequately treated
      